192 related articles for article (PubMed ID: 23564016)
21. Bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Curr Rheumatol Rep; 2003 Feb; 5(1):65-74. PubMed ID: 12590887
[TBL] [Abstract][Full Text] [Related]
22. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
23. Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.
van Beek E; Löwik C; Karperien M; Papapoulos S
Bone; 2006 Feb; 38(2):167-71. PubMed ID: 16165408
[TBL] [Abstract][Full Text] [Related]
24. Outwardly rectifying chloride current in rabbit osteoclasts is activated by hyposmotic stimulation.
Kelly ME; Dixon SJ; Sims SM
J Physiol; 1994 Mar; 475(3):377-89. PubMed ID: 8006823
[TBL] [Abstract][Full Text] [Related]
25. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Frith JC; Rogers MJ
J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells.
Das S; Edwards PA; Crockett JC; Rogers MJ
Biochim Biophys Acta; 2014 Apr; 1841(4):569-73. PubMed ID: 24369118
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
29. Expression of mouse osteoclast K-Cl Co-transporter-1 and its role during bone resorption.
Kajiya H; Okamoto F; Li JP; Nakao A; Okabe K
J Bone Miner Res; 2006 Jul; 21(7):984-92. PubMed ID: 16813519
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
Ebetino FH; Sun S; Cherian P; Roshandel S; Neighbors JD; Hu E; Dunford JE; Sedghizadeh PP; McKenna CE; Srinivasan V; Boeckman RK; Russell RGG
Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
[TBL] [Abstract][Full Text] [Related]
31. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.
Murakami H; Takahashi N; Sasaki T; Udagawa N; Tanaka S; Nakamura I; Zhang D; Barbier A; Suda T
Bone; 1995 Aug; 17(2):137-44. PubMed ID: 8554921
[TBL] [Abstract][Full Text] [Related]
32. Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts.
Takami M; Suda K; Sahara T; Itoh K; Nagai K; Sasaki T; Udagawa N; Takahashi N
Bone; 2003 Apr; 32(4):341-9. PubMed ID: 12689676
[TBL] [Abstract][Full Text] [Related]
33. Intracellular ClC-3 chloride channels promote bone resorption in vitro through organelle acidification in mouse osteoclasts.
Okamoto F; Kajiya H; Toh K; Uchida S; Yoshikawa M; Sasaki S; Kido MA; Tanaka T; Okabe K
Am J Physiol Cell Physiol; 2008 Mar; 294(3):C693-701. PubMed ID: 18234851
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
[TBL] [Abstract][Full Text] [Related]
35. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.
Mönkkönen H; Auriola S; Lehenkari P; Kellinsalmi M; Hassinen IE; Vepsäläinen J; Mönkkönen J
Br J Pharmacol; 2006 Feb; 147(4):437-45. PubMed ID: 16402039
[TBL] [Abstract][Full Text] [Related]
36. Effect of nitrogen-containing bisphosphonates on osteoclasts and osteoclastogenesis: an ultrastructural study.
Takagi Y; Inoue S; Fujikawa K; Matsuki-Fukushima M; Mayahara M; Matsuyama K; Endo Y; Nakamura M
Microscopy (Oxf); 2021 Jun; 70(3):302-307. PubMed ID: 33277903
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
Montalvetti A; Bailey BN; Martin MB; Severin GW; Oldfield E; Docampo R
J Biol Chem; 2001 Sep; 276(36):33930-7. PubMed ID: 11435429
[TBL] [Abstract][Full Text] [Related]
38. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
39. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Hirbe AC; Roelofs AJ; Floyd DH; Deng H; Becker SN; Lanigan LG; Apicelli AJ; Xu Z; Prior JL; Eagleton MC; Piwnica-Worms D; Rogers MJ; Weilbaecher K
Bone; 2009 May; 44(5):908-16. PubMed ID: 19442620
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
